National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients

Largest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System

CLEVELAND, Aug. 11, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the National Cancer Center Hospital (NCCH) of Japan has upgraded its original Cobalt MRIdian® MRI-Guided Radiation Therapy System to the MRIdian Linac System and has treated its first patients. The MRIdian system will enable National Cancer Center Hospital to offer advanced MRI-guided radiation therapy technology to cancer patients who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

NCC purchased its first MRIdian System in September 2016 following Shonin approval of the cobalt system from the Japanese Ministry of Health, Labour and Welfare (MHLW) the month prior. On the July 25, 2022, NCCH treated their first patient with full on table adaptive workflow on the upgraded Linac version of MRIdian. MRIdian Linac features linear accelerator delivery and enables daily on-table adaptive radiotherapy and real-time tracking to adjust radiation beam delivery dynamically for subtle anatomical changes that may occur, both during treatment delivery and throughout the course of treatment. Combined, these capabilities help clinicians improve targeting precision and thus deliver higher radiation doses.

"Over the past 6 years we've seen firsthand the benefits of real-time MRI-guidance and on-table adaptive treatment delivery and its value in improving outcomes for cancer patients, so we look forward to incorporating the MRIdian Linac system to further enhance our MRI-guided radiation therapy offerings," said Dr. Kazuaki Shimada, Director of National Cancer Center Hospital. "MRIdian's gating technology is unparalleled and allows us to be aggressive in our delivery of stereotactic body radiation therapy because we can feel confident that the dose is accurately reaching the target without collateral damage to surrounding healthy tissue, can offer the best medical care to the society," said Dr. Hiroshi Igaki, Chief, Department of Radiation Oncology.

Japan is the world's third largest market for radiation oncology and the National Cancer Center Hospital is one of Japan's leading national cancer treatment facilities, providing patient care for over 60 years. National Cancer Center is at the forefront of research in cancer treatment and plays a central role in training doctors, nurses, and other medical professionals to specialize in cancer medicine. 

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

Nearly 25,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

Disclaimer:
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

Safety Statement
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

SOURCE ViewRay, Inc.